Measures · D12 in 2027 · Part D · DD4 Drug Safety and Accuracy of Drug Pricing
Concurrent Use of Opioids and Benzodiazepines (COB)
Drug PlanMedication SafetySource: Prescription Drug Events
- What it measures
- While there may be instances where it is appropriate for concurrent use of opioids and benzodiazepines, the concurrent use of prescription opioids with benzodiazepines increases the risk of adverse events such as respiratory depression, overdose, and death.
- How it's calculated
- The measure is defined as the percentage of Part D beneficiaries, 18 years or older, with concurrent use of prescription opioids and benzodiazepines during the measurement period. Concurrent use is defined as overlapping days’ supply for an opioid and benzodiazepine of at least 30 cumulative days during the measurement period. Continuous enrollment (CE) is defined as continuously enrolled in a Medicare Part D contract during the measurement period, with one allowable gap in enrollment of up to one calendar month. The percentage is calculated as the number of CE beneficiaries in the denominator with at least two prescription claims for any benzodiazepines with unique dates of service (DOS) and concurrent use of opioids and benzodiazepines for at least 30 cumulative days during the measurement period (numerator) divided by the number of CE beneficiaries, 18 years or older, with at least two prescription claims for opioid medications with unique DOS and at least 15 cumulative days’ supply of opioids during the measurement period and an IPSD that occurs at least 30 days prior to the end of the measurement period (denominator). The COB measure is adapted from the Concurrent use of Opioids and Benzodiazepines measure that was developed and endorsed by the Pharmacy Quality Alliance (PQA). See the medication list for this measure. The COB measure is calculated using the NDC lists updated by the PQA. The complete NDC lists, including diagnosis codes, are posted along with these technical notes.
- Data source
- Prescription Drug Event (PDE) The data for this measure come from Prescription Drug Event (PDE) data submitted by drug plans to the CMS DDPS and accepted by the 2025 PDE submission deadline for annual Part D payment reconciliation with dates of service from January 1, 2025 – December 31, 2025. If the PDE edit results in the PDE being rejected by DDPS, then the PDE is not used in the Patient Safety measure calculations. If the PDE edit is informational and therefore does not result in the PDE being rejected, then the PDE is used in the Patient Safety measure calculations. Reminder, CMS uses the term “final action” PDE to describe the most recently accepted original, adjustment, or deleted PDE record representing a single dispensing event. Original and adjustment final action PDEs submitted by the sponsor and accepted by DDPS prior to the 2025 PDE submission deadline are used to calculate this measure. PDE adjustments made post- reconciliation were not reflected in this measure. Additional data sources include the CME, the CWF, and the EDS. The data cutoff date for all the additional data sources listed below such as the CME, CWF, and EDS is determined by the same PDE submission deadline for the annual Part D payment reconciliation. • CME is used for enrollment information and to identify beneficiaries who elected to receive hospice care. • CWF is used to identify exclusion diagnoses based on ICD-10-CM codes (on inpatient, outpatient, or carrier claims). • EDS is used to identify exclusion diagnoses based on ICD-10-CM codes (on inpatient, outpatient, or carrier claims).
- Measurement period
- 01/01/2025 – 12/31/2025
- Better when
- Lower
- Weight
- 1 (Process Measure)
- Star assignment
- Clustering
- Case-mix adjusted
- No
- In improvement measure
- Yes
- Used in CAI
- Yes
- Exclusions
Show
Contracts with 29 or fewer continuously enrolled beneficiaries (in the denominator). The following beneficiaries are excluded from the denominator if at any time during the measurement period: • In hospice • Cancer diagnosis • Sickle cell disease diagnosis • Palliative care • Cancer-related pain treatment diagnosis- Notes
- Part D drugs do not include drugs or classes of drugs, or their medical uses, which may be excluded from coverage or otherwise restricted under section 1927(d)(2) of the Act, except for smoking cessation agents. As such, these drugs, which may be included in the PQA medication or NDC lists, are excluded from CMS analyses.
- Disaster policy
- Higher measure star (2026-2027) for contracts with 25% or more enrolled affected by 2025 disasters.
From the 2027 Star Ratings Technical Notes (CMS).
Cut points over time
Score needed to earn each star level. Part D thresholds differ for MA-PD and standalone PDP contracts.
2027 star distribution
Not rated: Plan too new to be measured (94); Not enough data available (50); Plan not required to report measure (8)
Cut point bands
| Star year | Org type | 1★ | 2★ | 3★ | 4★ | 5★ |
|---|---|---|---|---|---|---|
| 2027 | MA-PD | > 20 % | > 16 % to <= 20 % | > 12 % to <= 16 % | > 8 % to <= 12 % | <= 8 % |
| 2027 | PDP | > 18 % | > 14 % to <= 18 % | > 11 % to <= 14 % | > 6 % to <= 11 % | <= 6 % |
Lowest-scoring contracts, 2027
| Contract | Parent | Members | Score | Stars | Δ | Shortfall to 4★ | Pctile |
|---|---|---|---|---|---|---|---|
| S8067 Avalon Insurance Company | CAPITAL BLUE CROSS | 1,340 | 22 | 1 | — | 11 | 0% |
| H9986 Florida Complete Care | Independent Living Systems, LLC | 1,218 | 45 | 1 | — | 33 | 0% |
| H5703 South Country Health Alliance | South Country Health Alliance | 499 | 36 | 1 | — | 24 | 0% |
| H4093 Provider Partners Health Plans | Rifkin Managed Care Holding, LLC | 860 | 33 | 1 | — | 21 | 0% |
| H5852 AHF | AIDS Healthcare Foundation | 594 | 30 | 1 | — | 18 | 1% |
| H5431 HealthSun Health Plans, Inc. | Elevance Health, Inc. | 68,863 | 29 | 1 | — | 17 | 1% |
| H5774 Triple S Advantage | Guidewell Mutual Holding Corporation | 121,384 | 28 | 1 | — | 16 | 1% |
| H2926 PrimeWest Health | PrimeWest Rural MN Health Care Access Initiative | 749 | 28 | 1 | — | 16 | 1% |
| H3124 Jefferson Health Plans | Thomas Jefferson University | 941 | 27 | 1 | — | 15 | 1% |
| H7779 American Health Advantage of Tennessee | Mitchell Family Office | 297 | 26 | 1 | — | 14 | 1% |
| H7239 Prominence Health Plan | Universal Health Services, Inc. | 2,843 | 25 | 1 | — | 13 | 2% |
| H5577 MCS Classicare | MHH Healthcare, L.P. | 361,020 | 25 | 1 | — | 13 | 2% |
| H2400 Abilis Health (HMO SNP) | BrightSpring Health Services, Inc. | 1,139 | 25 | 1 | — | 13 | 2% |
| H2392 Kansas Health Advantage | Kansas Superior Select | 873 | 24 | 1 | — | 12 | 2% |
| H9191 Provider Partners Health Plans | Rifkin Managed Care Holding, LLC | 1,339 | 24 | 1 | — | 12 | 2% |
| H9153 West Virginia Senior Advantage | SNP Holdings, LLC | 1,661 | 23 | 1 | — | 11 | 3% |
| H0764 UnitedHealthcare | UnitedHealth Group, Inc. | 1,751 | 23 | 1 | — | 11 | 3% |
| H0907 Wellpoint | Elevance Health, Inc. | 4,212 | 23 | 1 | — | 11 | 3% |
| H5420 UnitedHealthcare | UnitedHealth Group, Inc. | 65,911 | 23 | 1 | — | 11 | 3% |
| S5593 Highmark Blue Shield | Highmark Health | 17,320 | 19 | 1 | — | 8 | 3% |
| H8330 Tufts Health Plan | Point32Health, Inc. | 15,985 | 22 | 1 | — | 10 | 3% |
| H5377 Humana | Humana Inc. | 3,919 | 22 | 1 | — | 10 | 3% |
| H3708 American Health Advantage of Oklahoma | Mitchell Family Office | 549 | 22 | 1 | — | 10 | 3% |
| H1119 Valor Health Plan | The Schroer Group, Inc. | 2,494 | 22 | 1 | — | 10 | 3% |
| H4140 Doctors HealthCare Plans, Inc. | DOCTORS HEALTHCARE PLANS, INC. | 27,878 | 22 | 1 | — | 10 | 3% |
History
| Star year | Code | Name | Measured | Weight | Source |
|---|---|---|---|---|---|
| 2027 | D12 | Concurrent Use of Opioids and Benzodiazepines (COB) | 01/01/2025 – 12/31/2025 | 1 | Prescription Drug Events |